A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...
Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...
Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option. After ...
Weekly demand in the U.S. is up more than 600%. Last week, a study in the U.K. found that dexamethasone, a common steroid, increased survival in severely ill COVID-19 patients who needed help ...